Encefa
Develops biologics that specifically modulate a key age-related target, to fight neurodegenerative, auto-immune, and more broadly age-related diseases.
- dt and ls
- biotechnology
- horizon europe
- biotech and pharma
- woman founder
- radar de l'innovation
- tech for business
- eit ecosystem
- observatoire industrial tech
- observatoire deeptech
- neurology
- eit health
- biotech, medtech and e-health
- eit supernovas
- longevity
- observatoire healthtech
- chronic disease
- microbiology
- investor network (eit health)
- autoimmune
- alzheimers disease
- pathology
- investor network 2018 (eit health)
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor | €0.0 | round |
| investor | €0.0 | round | |
$250k | Seed | ||
| Total Funding | 000k | ||
| EUR | 2017 |
|---|---|
| Revenues | 0000 |
| EBITDA | 0000 |
| Profit | 0000 |
| EV | 0000 |
| EV / revenue | 00.0x |
| EV / EBITDA | 00.0x |
| R&D budget | 0000 |
Source: Company filings or news article
Related Content
Encefa, a French biotechnology firm established in 2016, is a spin-off from the Institut de Cerveau et Moelle Epiniere (ICM). The company is at the forefront of developing a novel, neuroprotective small molecule aimed at treating Parkinson's disease.
Encefa's core technology revolves around the modulation of the CD38 enzyme. This approach is designed to activate the autophagy-lysosomal pathway, a cellular cleaning process, and enhance the energy metabolism of cells. By targeting these fundamental cellular mechanisms, Encefa aims to protect neurons from the degenerative effects of Parkinson's disease.
The company operates in the highly specialized and research-intensive biotechnology market, with a specific focus on neurodegenerative disorders. As an early-stage venture, its business model is centered on research and development, with the goal of advancing its lead candidate through preclinical and clinical trials. The ultimate aim is likely to partner with larger pharmaceutical companies for late-stage development and commercialization, or to seek acquisition.
Keywords: biotechnology, neuroprotective, Parkinson's disease, small molecule, CD38 modulator, autophagy, lysosomal, neurodegeneration, ICM spin-off, drug development